{"id":650366,"date":"2023-05-04T17:50:01","date_gmt":"2023-05-04T17:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=650366"},"modified":"2023-05-04T17:50:01","modified_gmt":"2023-05-04T17:50:01","slug":"persistent-epithelial-defect-ped-market-size-share-epidemiology-and-competitive-landscape-report-2032-companies-dompe-farmaceutici-ocunexus-therapeutics-eyevance-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/persistent-epithelial-defect-ped-market-size-share-epidemiology-and-competitive-landscape-report-2032-companies-dompe-farmaceutici-ocunexus-therapeutics-eyevance-pharmaceuticals_650366.html","title":{"rendered":"Persistent Epithelial Defect (PED) Market Size, Share, Epidemiology and Competitive Landscape Report 2032 | Companies &#8211; Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1683180079.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Persistent Epithelial Defect (PED) Market Size, Share, Epidemiology and Competitive Landscape Report 2032 | Companies - Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals\" src=\"https:\/\/www.abnewswire.com\/uploads\/1683180079.jpeg\" alt=\"Persistent Epithelial Defect (PED) Market Size, Share, Epidemiology and Competitive Landscape Report 2032 | Companies - Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Persistent Epithelial Defect Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Persistent Epithelial Defect (PED) &#8211; Market Insights, Epidemiology, and Market Forecast &#8211; 2032\u2019 report delivers an in-depth understanding of the Persistent Epithelial Defect (PED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">DelveInsight launched a new report on <strong>Persistent Epithelial Defect (PED) Market Insights, Epidemiology, and Market Forecast 2032<\/strong>.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &lsquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/persistent-epithelial-defect-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Persistent Epithelial Defect (PED) Market Report 2032<\/a>&rsquo; report delivers an in-depth understanding of the Persistent Epithelial Defect (PED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Persistent Epithelial Disease Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">Persistent Epithelial Disease, also known as persistent corneal epithelial defects (PEDs or PCEDs), results from the failure of rapid re-epithelialization and closure within 10&ndash;14 days after a corneal injury, even with standard supportive treatment. PED is defined as &ldquo;defects persisting for more than 2 weeks without improvement despite conventional treatment, such as non-preservative artificial tears or extended wear soft contact lenses&rdquo;. PEDs commonly extend into the stromal layer, causing stromal melting, secondary ulceration, and stromal scarring. Also, an insult to the cornea resulting in an acute epithelial defect is a lesion that usually heals over the 7&ndash;14 days time frame. In contrast, a persistent epithelial defect is unable to close within this normal interval.<\/p>\n<p style=\"text-align: justify;\"><strong>Persistent Epithelial Disease Epidemiology insights:<\/strong><\/p>\n<p style=\"text-align: justify;\">The total Incident population of Persistent Epithelial Defect (PED) in 7MM countries was estimated to be 238,058 cases in 2019.<\/p>\n<p style=\"text-align: justify;\"><strong>Persistent Epithelial Disease Key Companies:<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Dompe Farmaceutici<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; OcuNexus Therapeutics\/Eyevance Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; Noveome Biotherapeutics<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; RegeneRx Biopharmaceuticals<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&bull; Recordati Rare Diseases\/Mimetech<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;Request for a detailed sample copy of the report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/persistent-epithelial-defect-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/persistent-corneal-epithelial-defects-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/persistent-epithelial-defect-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Persistent Epithelial Disease Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The Persistent Epithelial Defect (PED) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Persistent Epithelial Defect (PED) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.<\/p>\n<p style=\"text-align: justify;\">The first step in the management of any epithelial abnormality is to determine the etiology of the disease. Currently, &ldquo;bandage&rdquo; methods are used to help re-epithelialize a cornea. The current approaches include Aggressive lubrication, Punctal occlusion, Bandage soft contact lens, Pressure patching, Tetracyclines, prophylactic topical antibiotics and steroids. For the treatment of refractory cases, Amniotic membrane grafting, autologous serum, Scleral contact lenses, and others have been recommended. In severe cases, a conjunctival graft may be placed over the cornea.&nbsp;<\/p>\n<p style=\"text-align: justify;\">This section includes a glimpse of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/persistent-epithelial-defect-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Persistent Epithelial Defect market<\/a> in 7MM. The market size of PED in the seven major markets was found to be USD xx million in 2019.<\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1 Key Insight<\/p>\n<p style=\"text-align: justify;\">2 Executive Summary of Persistent Epithelial Defect (PED)<\/p>\n<p style=\"text-align: justify;\">3 Persistent Epithelial Defect (PED) Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4 Disease Background and Overview: Persistent Epithelial Defect (PED)<\/p>\n<p style=\"text-align: justify;\">5 Case Reports<\/p>\n<p style=\"text-align: justify;\">6 Persistent Epithelial Defect (PED) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">7 United States Epidemiology<\/p>\n<p style=\"text-align: justify;\">8 EU5 Epidemiology<\/p>\n<p style=\"text-align: justify;\">9 Japan Epidemiology<\/p>\n<p style=\"text-align: justify;\">10 Current Persistent Epithelial Defect (PED) Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">11 Unmet needs<\/p>\n<p style=\"text-align: justify;\">12 Persistent Epithelial Defect (PED) Marketed Drugs<\/p>\n<p style=\"text-align: justify;\">13 Persistent Epithelial Defect (PED) Emerging Drugs<\/p>\n<p style=\"text-align: justify;\">14 Persistent Epithelial Defect (PED) 7MM Market Analysis<\/p>\n<p style=\"text-align: justify;\">15 United States<\/p>\n<p style=\"text-align: justify;\">16 EU-5 countries: Market Outlook<\/p>\n<p style=\"text-align: justify;\">17 Japan Market Outlook<\/p>\n<p style=\"text-align: justify;\">18 Persistent Epithelial Defect (PED) Market Drivers<\/p>\n<p style=\"text-align: justify;\">19 Persistent Epithelial Defect (PED) Market Barriers<\/p>\n<p style=\"text-align: justify;\">20 SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">21 Reimbursement and market access<\/p>\n<p style=\"text-align: justify;\">22 Appendix<\/p>\n<p style=\"text-align: justify;\">23 DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">24 Disclaimer<\/p>\n<p style=\"text-align: justify;\">25 About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Download Persistent Epithelial Defect Market Report 2032: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/persistent-epithelial-defect-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/persistent-corneal-epithelial-defects-market<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=persistent-epithelial-defect-ped-market-size-share-epidemiology-and-competitive-landscape-report-2032-companies-dompe-farmaceutici-ocunexus-therapeutics-eyevance-pharmaceuticals\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=persistent-epithelial-defect-ped-market-size-share-epidemiology-and-competitive-landscape-report-2032-companies-dompe-farmaceutici-ocunexus-therapeutics-eyevance-pharmaceuticals\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Persistent Epithelial Defect Market DelveInsight\u2019s \u2018Persistent Epithelial Defect (PED) &#8211; Market Insights, Epidemiology, and Market Forecast &#8211; 2032\u2019 report delivers an in-depth understanding of the Persistent Epithelial Defect (PED), historical and forecasted epidemiology as well as the market trends in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/persistent-epithelial-defect-ped-market-size-share-epidemiology-and-competitive-landscape-report-2032-companies-dompe-farmaceutici-ocunexus-therapeutics-eyevance-pharmaceuticals_650366.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-650366","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/650366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=650366"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/650366\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=650366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=650366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=650366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}